Promising New Lung Cancer Therapy to be Presented at Prestigious World Conference
San Francisco, CA & Lianyungang, China – July 22, 2025 – IDEAYA Biosciences, Inc. (NASDAQ: IDYA) and Jiangsu Hengrui Medicine Co., Ltd. (600737.SS) today announced that IDE849 (also known as SHR-4849), a novel antibody-drug conjugate (ADC) targeting DLL3, is slated for an oral presentation at the upcoming IASLC 2025 World Conference on Lung Cancer. This significant presentation underscores the potential of IDE849 as a first-in-class therapeutic for patients with specific types of lung cancer.
The IASLC World Conference on Lung Cancer is a globally recognized event that brings together leading oncologists, researchers, and healthcare professionals to share groundbreaking advancements in the fight against lung cancer. The inclusion of IDE849 in the oral presentation program highlights the promising early clinical data and scientific merit of this investigational therapy.
IDE849 is being developed through a strategic collaboration between IDEAYA Biosciences and Hengrui Pharmaceuticals. This innovative ADC is designed to selectively target tumor cells expressing Delta-like ligand 3 (DLL3), a protein that is frequently found on the surface of small cell lung cancer (SCLC) cells and other neuroendocrine tumors, but is expressed at much lower levels in healthy tissues. By utilizing a highly potent topoisomerase 1 (TOP1) inhibitor payload, IDE849 aims to deliver a concentrated dose of chemotherapy directly to cancer cells, thereby enhancing efficacy while potentially minimizing systemic toxicity.
The development of IDE849 represents a significant step forward in the pursuit of more targeted and effective treatments for lung cancer. The “first-in-class” designation suggests that if approved, IDE849 would be the first therapy of its kind to leverage this specific mechanism of action for lung cancer, potentially offering a new avenue of treatment for patients who may not respond to or have progressed on existing therapies.
Further details regarding the specific data to be presented at the IASLC 2025 World Conference on Lung Cancer will be made available closer to the event. The companies are enthusiastic about sharing these findings with the scientific and medical community and are committed to advancing the development of IDE849 with the ultimate goal of improving outcomes for patients battling lung cancer.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC’ at 2025-07-22 17:01. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.